Table 1.
Characteristics of women included in the study cohort by type of progestin oral contraceptive used (n = 1,148,183)
| Desogestrel | Drospirenone | Ethynodiol Diacetate | Levonorgestrel | Norethindrone Acetate | Norethindrone | Norgestimate | Norgestrel | |
|---|---|---|---|---|---|---|---|---|
| Number of patients | 139,871 | 224,408 | 17,295 | 180,720 | 93,818 | 234,105 | 228,276 | 29,690 |
| Age | 28.7 | 29.0 | 28.8 | 29.0 | 30.5 | 29.7 | 26.9 | 29.7 |
| Mean follow up (days) | 327 | 272 | 327 | 304 | 240 | 230 | 307 | 249 |
| Number of cases | 267 | 488 | 33 | 349 | 200 | 433 | 499 | 56 |
| Covariates (%) | ||||||||
| CKD † | 0.15 | 0.09 | 0.08 | 0.09 | 0.12 | 0.15 | 0.08 | 0.19 |
| Diabetes | 4.10 | 4.10 | 4.41 | 3.93 | 4.13 | 4.12 | 3.37 | 5.43 |
| Hypertension | 8.34 | 8.47 | 8.53 | 8.62 | 9.78 | 8.89 | 6.55 | 10.82 |
| IBD* | 0.94 | 1.03 | 1.22 | 1.00 | 1.03 | 0.85 | 0.75 | 0.98 |
| Obesity | 11.59 | 12.53 | 12.44 | 11.22 | 10.75 | 10.08 | 9.50 | 13.60 |
| PCOS ᶋ | 4.47 | 5.78 | 5.00 | 2.11 | 2.80 | 2.81 | 2.21 | 3.48 |
| PTS (PMS/PMDD) ‡ | 3.63 | 5.53 | 3.04 | 3.01 | 3.26 | 1.95 | 1.69 | 2.73 |
| Smoking | 6.62 | 5.94 | 8.48 | 7.36 | 6.43 | 6.49 | 6.97 | 9.00 |
| ACEI/ARB § | 0.50 | 0.47 | 0.56 | 0.60 | 0.75 | 0.67 | 0.42 | 0.80 |
| NSAIDS ʗ | 5.67 | 4.84 | 5.79 | 5.56 | 5.13 | 5.90 | 4.77 | 6.09 |
| Spironolactone | 0.43 | 0.74 | 0.84 | 0.28 | 0.32 | 0.19 | 0.32 | 0.29 |
| Other Medications ʒ | 0.46 | 0.36 | 0.56 | 0.46 | 0.37 | 0.35 | 0.27 | 0.44 |
*Inflammatory bowel disease
† CKD = Chronic Kidney Disease
ᶋ PCOS = Polycystic Ovary Syndrome
‡ PTS (PMS/PMDD) = premenstrual tension syndrome (premenstrual syndrome and premenstrual dysphoric disorder)
§ ACE/ARB = angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
ʗ NSAID = non-steroidal anti-inflammatory drugs
ʒ Other medications = diuretics, heparin, cyclosporine, tacrolimus, trimethoprim, and penicillin G